(Q24607823)

2

0 references

F A Campbell

3

0 references

D J Reynolds

4

0 references

R A Moore

5

0 references

H J McQuay

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

6

0 references

language of work or name

English

0 references

publication date

7 July 2001

0 references

published in

The BMJ

0 references

volume

323

0 references

page(s)

16-21

0 references

issue

7303

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Superiority of Nabilone over Prochlorperazine as an Antiemetic in Patients Receiving Cancer Chemotherapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

The number needed to treat: a clinically useful measure of treatment effect

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Marijuana: medical implications

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Marihuana as medicine. A plea for reconsideration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Nabilone: An Effective Antiemetic in Patients Receiving Cancer Chemotherapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Nabilone: an alternative antiemetic for cancer chemotherapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Medicinal applications of delta-9-tetrahydrocannabinol and marijuana

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Confidence intervals for the number needed to treat

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Effect of nabilone on nausea and vomiting after total abdominal hysterectomy.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=34325

Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study

28 November 2018

1 reference

12 December 2020

THC or Compazine for the cancer chemotherapy patient--the UCLA study. Part II: Patient drug preference

1 reference

12 December 2020

Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis

1 reference

12 December 2020

Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine

1 reference

12 December 2020

Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo

1 reference

12 December 2020

Cannabis and cancer chemotherapy

1 reference

12 December 2020

Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy

1 reference

12 December 2020

Inhalation marijuana as an antiemetic for cancer chemotherapy

1 reference

12 December 2020

Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Marijuana as an antiemetic drug: how useful is it today? Opinions from clinical oncologists

1 reference

12 December 2020

In search of an effective antiemetic: a nusring staff participates in marijuana research

1 reference

12 December 2020

The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy

1 reference

12 December 2020

Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis

1 reference

12 December 2020

Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis

1 reference

12 December 2020

A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy

1 reference

12 December 2020

delta 9-tetrahydrocannabinol in clinical oncology

1 reference

12 December 2020

Physiologic Observations in a Controlled Clinical Trial of the Antiemetic Effectiveness of 5, 10, and 15 mg of Δ9-Tetrahydrocannabinol in Cancer Chemotherapy. Ophthalmologic Implications

1 reference

12 December 2020

The Controlled Substances Therapeutic Research Act in the State of Washington

1 reference

12 December 2020

Comparative Trial of the Antiemetic Effects of THC and Haloperidol

1 reference

12 December 2020

Antiemetic Effect of Δ9-Tetrahydrocannabinol in Chemotherapy-Associated Nausea and Emesis As Compared to Placebo and Compazine

1 reference

12 December 2020

Cannabis and cancer chemotherapy. A comparison of oral delta-9-thc and prochlorperazine

1 reference

12 December 2020

[Levonantradol in the treatment of nausea and vomiting caused by cytostatic drugs (author's transl) clinical studies]

1 reference

12 December 2020

Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting

1 reference

12 December 2020

A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy

1 reference

12 December 2020

Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy

1 reference

12 December 2020

A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients

1 reference

12 December 2020

Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy

1 reference

12 December 2020

Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin

1 reference

12 December 2020

A randomised multicentre single blind comparison of a cannabinoid anti-emetic (Levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy

1 reference

12 December 2020

Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis

1 reference

12 December 2020

Federal foolishness and marijuana

1 reference

12 December 2020

The cannabis remedy--wonder worker or evil weed?

1 reference

12 December 2020

Identifiers

DOI

10.1136/BMJ.323.7303.16

1 reference

1672618

1672618

1 reference

1 reference

1 reference